Meningiomas

Published on 20/03/2015 by admin

Filed under Pathology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2471 times

43

Meningiomas

MENINGIOMAS

Meningiomas arise from meningothelial (arachnoid) cells in the leptomeninges. These cells have both epithelial and mesenchymal characteristics, which are shown by meningiomas in a spectrum of diverse histologic appearances. The World Health Organization (WHO) classification recognizes several variants of meningioma (Table 43.1). Differentiation towards the epithelial end of the histologic spectrum is represented by the meningothelial and secretory variants. Differentiation towards the mesenchymal end of the spectrum is represented by the fibrous and metaplastic variants.

Table 43.1

WHO classification (2007) of meningiomas

WHO grade 1

Meningothelial

Fibrous (fibroblastic)

Transitional (mixed)

Psammomatous

Angiomatous

Microcystic

Secretory

Lymphoplasmacyte-rich

Metaplastic

WHO grade 2

Atypical

Chordoid

Clear cell

WHO grade 3

Anaplastic

Papillary

Rhabdoid

Meningiomas occur throughout the central nervous system (CNS), but have a predilection for certain sites (Fig. 43.1). Unusual sites include the ventricles and the epidural space. Depending on its location, a meningioma can grow for a prolonged period and to a considerable size before producing symptoms and signs. It may lead to increased intracranial pressure, loss of CNS function, or epilepsy. Some meningiomas are incidental post-mortem findings (Fig. 43.2).

The site of a meningioma and any involvement of local structures are major prognostic factors because they affect surgical accessibility and determine whether complete removal can be achieved. Approximately 15% of meningiomas that seem to have been completely resected recur.

Histologic assessment of a meningioma provides some information about its biologic behavior. An increased tendency to recur and a shorter interval to recurrence are properties of meningiomas that show malignant architectural and cytologic features. Such features are present in atypical and, to a greater extent, in anaplastic meningiomas, and develop progressively in meningiomas that recur several times. Infiltration of the brain is the most important histologic predictor of a high likelihood of local recurrence (see below). Other features are less reliable in predicting behavior. Even cytologically bland meningiomas can behave in a locally aggressive manner.

Not all meningeal neoplasms are meningiomas. Metastatic neoplasms (see Chapter 46); hemangiopericytomas, hemangioblastomas, melanocytic neoplasms, and various mesenchymal neoplasms (see all in Chapter 45), may be located in the meninges. The term angioblastic meningioma, previously used for angiomatous meningiomas, hemangiopericytomas, and hemangioblastomas, is obsolete. Meningeal hemangiopericytomas/solitary fibrous tumors and hemangioblastomas are morphologically, immunophenotypically, and genetically distinct from meningiomas.

MACROSCOPIC APPEARANCES

Meningiomas arising around the cerebral convexities are generally spherical because they can displace underlying brain (Fig. 43.3). The shape of other meningiomas is constrained by their location, e.g. optic nerve meningiomas are fusiform. Meningiomas occasionally envelop rather than displace adjacent CNS structures (Fig. 43.4). Some meningiomas, particularly those on the sphenoid ridge, grow as plaques within the dura (en plaque meningioma).

Most meningiomas have a smooth or slightly lobulated surface and a rubbery consistency (Fig. 43.5). They are usually solid on sectioning, but may have a soft, granular texture, and there may be obvious interlacing bands of fibrous tissue. Rarer variants may have specific macroscopic features, e.g. the microcystic meningioma has a gelatinous texture and the psammomatous meningioma feels gritty.

The attached dura should be inspected for separate nodules of tumor, and the relationship between dura and tumor should be examined histologically (Fig. 43.6). Invasion of adjacent bone may be evident at operation, and pieces of bone may be submitted for examination (Fig. 43.7). The infiltrated bone often shows hyperostosis, a feature that can, however, occur adjacent to meningiomas even in the absence of bony invasion.

MICROSCOPIC APPEARANCES

Meningiomas exhibit a wide range of histologic patterns. Furthermore, a single meningioma may show a combination of patterns. The meningothelial, transitional, and fibrous variants predominate, forming a histologic continuum that should be regarded as prototypical of this neoplasm because their features appear, to a greater or lesser extent, in other variants as well.

Meningothelial meningiomas consist of sheets or lobules of oval cells that form rudimentary meningothelial whorls in a few places. Cytologic borders are indistinct. Single small nucleoli and nuclear pseudoinclusions formed by invaginations of the nuclear membrane are common (Fig. 43.8).

Fibrous meningiomas consist of spindle-shaped cells associated with variable amounts of pericellular collagen (Fig. 43.9).

Meningothelial and fibrous areas are combined in transitional meningiomas, which also contain widespread whorls and scattered psammoma bodies (Fig. 43.10).

The criteria for diagnosing these variants of meningioma are subjective and a clear distinction is not always possible. This is also true for other variants of meningioma. For example, psammomatous meningioma is not defined by a specific density of psammoma bodies.

Focal cytologic pleomorphism in association with large hyperchromatic nuclei and in the absence of an increased mitotic count may be seen in classic meningiomas. It does not indicate a worse prognosis, being regarded as a degenerative phenomenon.

Foci of foamy (xanthomatous) cells are frequently found in meningiomas (Fig. 43.11), and should not be mistaken for micronecrosis.

Other variants of meningioma (Table 43.2) have distinctive architectural and cytologic features which are usually combined with the prototypical histology described above (Figs 43.1243.17).

Table 43.2

Characteristics of variants of classic (WHO grade 1) meningiomas

Psammomatous

A transitional meningioma with many psammoma bodies

Intraspinal, orbital, and olfactory groove meningiomas are often psammomatous

Angiomatous

Multiple blood vessels of varying size among groups of meningothelial cells

Vessels tend to have thickened, hyaline walls

Intervening neoplastic cells show moderate nuclear pleomorphism

Microcystic

Cytoplasmic processes separated by extracellular fluid to produce a lacy meshwork of microcysts

Groups of thick-walled blood vessels and foamy cells

Moderate nuclear pleomorphism

Sparse whorls and psammoma bodies

Secretory

PAS-positive globular inclusions within intracytoplasmic lumina lined by microvilli The microvilli are not usually discernible except by electron microscopy

Surrounding cells are immunoreactive for cytokeratins

Lymphoplasmacyte-rich

Abundant lymphocytes and plasma cells appear as an inflammatory infiltrate

May show germinal centers

May occupy a spectrum with chordoid variant

Metaplastic

Mesenchymal differentiation (i.e. lipomatous, cartilaginous, osseous)

It is clear that some histologic variants have a more aggressive behavior than others, even when a meningioma’s site and the completeness of its resection have been taken into account. This variation is reflected in three levels of WHO grade (see Table 43.1). WHO grade 2 is assigned to atypical, clear cell and chordoid meningiomas (Table 43.3, Figs 43.1843.20), which show an increased frequency of recurrence, as do grade 3 anaplastic, papillary and rhabdoid meningiomas (Figs 43.2143.23), which are also more likely to exhibit malignant behavior, such as invasion of local structures or metastasis. Atypical and anaplastic meningiomas lie on a histologic continuum, but in the current WHO classification have been divided mainly on the basis of mitotic count (see Table 43.3). This nomenclature does not apply to meningeal sarcomas (see Chapter 45); while anaplastic meningiomas may contain sarcomatoid areas, they retain histologic features that identify them as meningiomas. The term ‘meningosarcoma’ is obsolete.

Table 43.3

Characteristics of WHO grade 2/3 meningiomas

WHO grade 2

Atypical

Increased mitotic count: ≥4/10 hpfs

With or without:

Scattered small areas of spontaneous necrosis (i.e. not related to embolization or radiotherapy)

Patternless growth

High nuclear:cytoplasmic ratio

Cells with prominent nucleoli

Chordoid

Lobulated or meningothelial architecture

Columns of vacuolated cells in a mucoid stroma plus scattered lymphoplasmacytoid infiltrates

Clear cell

Sheets/lobules of oval or elongated cells with abundant intracytoplasmic glycogen

Fibrous bands/hyalinization

Sparse whorl formation

WHO grade 3

Anaplastic

Increased mitotic count: ≥ 20/10 hpfs

Usually with:

Patternless growth

Foci of marked cytological pleomorphism

Multiple large foci of spontaneous necrosis

Papillary

Found particularly in young patients

Focal perivascular (pseudo)-papillary architecture in conjunction with classic patterns

High mitotic count

Tendency to invade local structures

Rhabdoid

Groups of rhabdoid cells are found in the setting of anaplastic features

High mitotic count

Tendency to occur in recurrent tumors

hpfs, high powered fields.

Invasion of the brain is an adverse prognostic feature (Fig. 43.24), but should be diagnosed with care. Tumor cells must breach the pia, invading brain parenchyma and eliciting reactive changes, such as astrocytosis. Superficial invasion along the subarachnoid space is not considered to be brain invasion. Brain invasion can be a feature of meningiomas that, on the basis of their cytological features, would be classified as WHO grade I, II, or III. However, when present in a meningioma with grade 1 cytological features, brain invasion is associated with an increased rate of recurrence, and such a tumor is classified as WHO grade II.

Meningiomas are immunoreactive for vimentin (Fig. 43.25), and most meningiomas, particularly those with epithelial qualities, immunolabel with antibodies to epithelial membrane antigen (EMA) (Fig. 43.26). Fibrous meningiomas tend to show only focal labeling for EMA. Approximately 25% of meningiomas show focal immunoreactivity for cytokeratins. The neoplastic cells surrounding

image DIFFERENTIAL DIAGNOSIS OF MENINGIOMA

Variant Differential diagnosis Distinguishing histologic features
Meningothelial meningioma Carcinoma Is much more commonly and diffusely immunoreactive for cytokeratins
Usually shows more anaplasia and mitotic activity
Has more clearly defined cytoplasmic margins
Melanocytic neoplasm Is frequently immunoreactive for S-100 and HMB-45
Is not immunoreactive for EMA
May contain melanosomes on ultrastructural examination
Has more clearly defined cytoplasmic margins
May have more prominent nucleoli
Glioma Usually shows a diffuse pattern of brain infiltration
Is usually immunoreactive for GFAP
Is not immunoreactive for EMA, except focally in some chordoid gliomas
Fibrous meningioma Astrocytoma As above for differentiating glioma from meningothelial meningioma
Schwannoma Shows a pericellular reticulin pattern
Is diffusely immunoreactive for S-100
Is not immunoreactive for EMA
Solitary fibrous tumor Is immunoreactive for CD34, but not EMA
Angiomatous meningioma Arteriovenous malformation Shows an absence of meningothelial cells
Includes entrapped gliotic brain tissue
Hemangiopericytoma May be focally immunoreactive for CD34, CD57, and BCL2
Has a pericellular basal lamina
Shows no desmosomes on electron microscopy
Microcystic meningioma Astrocytoma As above for differentiating glioma from meningothelial meningioma
Hemangioblastoma Is not immunoreactive for EMA
Reveals a characteristic arrangement of stromal cells and capillaries
Contains no junctions on electron microscopy
Lymphoplasmacyte-rich meningioma Plasmacytoma Demonstrates light chain restriction in proliferating plasma cells
Meningeal inflammation Contains few groups of meningothelial cells
May include neutrophils
Clear cell meningioma Renal cell carcinoma Is usually immunoreactive for cytokeratins
Chordoid meningioma Chordoma Shows widespread immunoreactivity for S-100 protein and cytokeratins permeates bone
Papillary meningioma Ependymoma As above for differentiating glioma from meningothelial meningioma
Carcinoma As above for differentiating carcinoma from meningothelial meningioma
Choroid plexus carcinoma Is usually immunoreactive for cytokeratins and Kir7.1

the characteristic globules in secretory meningiomas label strongly with antibodies to cytokeratin (see Fig. 43.15d). Some meningiomas contain scattered cells that are immunoreactive for S-100 protein. There is no immunoreactivity for GFAP, except in some rhabdoid tumors.

The proportion of neoplastic cells labeled by Ki-67 antibodies and other cell cycle specific markers is greater in atypical and anaplastic meningiomas than in prototypical classic meningiomas. In some series, Ki-67 labeling indices have correlated with rapidity of recurrence, but controversy surrounds the value of the Ki-67 labeling index as an independent prognostic indicator and its use in the individual case.

Ultrastructural features of meningiomas include interdigitating processes, intermediate filaments, desmosomes, and hemidesmosomes. Intercellular collagen deposition is found in fibrous variants.

REFERENCES

Bondy, M., Ligoni, B.L. Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol.. 1996;29:197–205.

Boström, J., Meyer-Puttlitz, B., Wolter, M., et al. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol.. 2001;159:661–669.

Epari, S., Sharma, M.C., Sarkar, C., et al. Chordoid meningioma, an uncommon variant of meningioma: a clinicopathologic study of 12 cases. J Neurooncol.. 2006;78:263–269.

Germano, I.M., Edwards, M.S., Davis, R.L., et al. Intracranial meningiomas of the first two decades of life. J Neurosurg.. 1994;80:447–453.

Haberler, C., Jarius, C., Lang, S., et al. Fibrous meningeal tumours with extensive non-calcifying collagenous whorls and glial fibrillary acidic protein expression: the whorling-sclerosing variant of meningioma. Neuropathol Appl Neurobiol.. 2002;28:42–47.

Kepes, J.J. Presidential address: the histopathology of meningiomas. A reflection of origins and expected behavior? J Neuropathol Exp Neurol.. 1986;45:95–107.

Lamszus, K., Kluwe, L., Matschke, J., et al. Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet.. 1999;110:103–110.

Larson, J.J., Tew, J.M., Jr., Simon, M., et al. Evidence for clonal spread in the development of multiple meningiomas. J Neurosurg.. 1995;83:705–709.

Leone, P.E., Bello, M.J., de Campos, J.M., et al. NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene.. 1999;18:2231–2239.

Longstreth, W.T., Jr., Dennis, L.K., McGuire, V.M., et al. Epidemiology of intracranial meningioma. Cancer.. 1993;72:639–648.

Ludwin, S.K., Rubinstein, L.J., Russell, D.S. Papillary meningioma: a malignant variant of meningioma. Cancer.. 1975;36:1363–1373.

Mahmood, A., Caccamo, D.V., Tomecek, F.J., et al. Atypical and malignant meningiomas: a clinicopathological review. Neurosurgery.. 1993;33:955–963.

Maier, H., Ofner, D., Hittmair, A., et al. Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg.. 1992;77:616–623.

Menon, A.G., Rutter, J.L., von Sattel, J.P., et al. Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative ’tumor progression’ locus. Oncogene.. 1997;14:611–616.

Olivero, W.C., Lister, J.R., Elwood, P.W. The natural history and growth rate of asymptomatic meningiomas: a review of 60 patients. J Neurosurg.. 1995;83:222–224.

Pasquier, B., Gasnier, F., Pasquier, D., et al. Papillary meningioma. Clinicopathologic study of seven cases and review of the literature. Cancer.. 1986;58:299–305.

Perry, A., Fuller, C.E., Judkins, A.R., et al. INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas. Mod Pathol.. 2005;18:951–958.

Perry, A., Giannini, C., Raghavan, R., et al. Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol.. 2001;60:994–1003.

Perry, A., Scheithauer, B.W., Stafford, S.L., et al. “Rhabdoid” meningioma: an aggressive variant. Am J Surg Pathol.. 1998;22:1482–1490.

Perry, A., Scheithauer, B.W., Stafford, S.L., et al. “Malignancy” in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer.. 1999;85:2046–2056.

Perry, A., Stafford, S.L., Scheithauer, B.W., et al. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol.. 1997;21:1455–1465.

Rajaram, V., Brat, D.J., Perry, A. Anaplastic meningioma versus meningeal hemangiopericytoma: immunohistochemical and genetic markers. Hum Pathol.. 2004;35:1413–1418.

Riemenschneider, M.J., Perry, A., Reifenberger, G. Histological classification and molecular genetics of meningiomas. Lancet Neurol.. 2006;5:1045–1054.

Simon, M., von Deimling, A., Larson, J.J., et al. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res.. 1995;55:4696–4701.

Stafford, S.L., Perry, A., Suman, V.J., et al. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc.. 1998;73:936–942.

Weber, R.G., Boström, J., Wolter, M., et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A.. 1997;94:14719–14724.

Wellenreuther, R., Kraus, J.A., Lenartz, D., et al. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol.. 1995;146:827–832.

Wolfsberger, S., Doostkam, S., Boecher-Schwarz, H.G., et al. Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature. Neurosurg Rev.. 2004;27:238–245.